Despite the availability of a variety of contraceptive methods, millions of women still have an unmet need for contraceptive choices. Short-acting methods are plagued by issues with adherence, leading to imperfect or inconsistent use and subsequent unintended pregnancy. Long-acting contraceptive methods such as intrauterine devices and contraceptive implants, while providing highly effective and safe contraception, do not meet the needs of all women, often due to cost, access or acceptability issues. Several new methods are in various stages of development and are designed to address the shortcomings of current methods. Providers should be aware of these future options and how they might better meet women's needs.
AlkemaLKantorovaVMenozziCBiddlecomA. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet381(9878), 1642–1652 (2013).
2.
DarrochJESinghS. Trends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveys. Lancet381(9879), 1756–1762 (2013).
3.
FinerLBZolnaMR. Shifts in intended and unintended pregnancies in the United States, 2001–2008. Am. J. Public Heath104(Suppl. 1), S43–S48 (2014).
4.
FrostJJSinghSFinerLB. Factors associated with contraceptive use and nonuse, United States, 2004. Perspect. Sex. Reprod. Health39(2), 90–99 (2007).
5.
FinerLBHenshawSK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect. Sex. Reprod. Health38(2), 90–96 (2006).
6.
United Nations. Department of Economic and Social Affairs Population Division. World Contraceptive Use 2011. United Nations, NY, USA (2011). www.un.org.
7.
JonesJMosherWDanielsK. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. National Health Statistics Reports (2012). www.cdc.gov.
CONRAD. Research grid: contraceptive research. www.conrad.org.
11.
HubacherDKimaniJSteinerMJSolomonMNduggaMB. Contraceptive implants in Kenya: current status and future prospects. Contraception75(6), 468–473 (2007).
12.
RaymondEGSinghMArcherDFSaxenaBBBakerJColeD. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants. Fertil. Steril.66(6), 954–961 (1996).
13.
DarneyPDKlaisleCMMonroeSECookCEPhillipsNRSchindlerA. Evaluation of a 1–year levonorgestrel-releasing contraceptive implant: side effects, release rates, and biodegradability. Fertil. Steril.58(1), 137–143 (1992).
14.
United Nations population division: world contraceptive use 2011. www.un.org.
15.
HubacherDFinerLBEspeyE. Renewed interest in intrauterine contraception in the United States: evidence and explanation. Contraception83(4), 291–294 (2011).
GlasierAFCameronSTFinePMUlipristal acetate versus levonorgestrel for emergency contraception: a randomised non-%inferiority trial and meta-analysis. Lancet375(9714), 555–562 (2010).
20.
JensenJT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception87(3), 314–318 (2013).
21.
BrennerRMSlaydenODNathATsongYYSitruk-WareR. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception81(4), 336–342 (2010).
22.
LiYZhangSMChenF [A multi-%center randomized controlled trial of intrauterine device use in Chinese women]. Zhonghua yi xue za zhi91(45), 3172–3175 (2011).
23.
WangLYLiSZWuSYZhaoYHWangY. [A random control study of indomethacin-containing MYCu intrauterine contraceptive device for 60 months]. Zhonghua yi xue za zhi93(7), 496–499 (2013).
24.
MeirikORowePJPeregoudovAPiaggioGPetzoldM. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception80(2), 133–141 (2009).
25.
BaramIWeinsteinATrussellJ. The IUB, a newly invented IUD: a brief report. Contraception89(2), 139–141 (2014).
MalcolmRKFetherstonSMMccoyCFBoydPMajorI. Vaginal rings for delivery of HIV microbicides. Int. J. Womens Health4, 595–605 (2012).
28.
MishellDRJrLumkinME. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil. Steril.21(2), 99–103 (1970).
29.
NathASitruk-WareR. Progesterone vaginal ring for contraceptive use during lactation. Contraception82(5), 428–434 (2010).
30.
HelblingIMIbarraJCLunaJA. The optimization of an intravaginal ring releasing progesterone using a mathematical model. Pharm. Res.31(3), 795–808 (2014).
Population Council: New USAID cooperative agreement with the population council facilitates contraceptive development, supports introduction of new methods in low resource settings. www.popcouncil.org.
33.
BracheVPayanLJFaundesA. Current status of contraceptive vaginal rings. Contraception87(3), 264–272 (2013).
BracheVMishellDRLahteenmakiPOvarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception63(5), 257–261 (2001).
36.
SivinIMishellDRJrAlvarezFContraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception71(2), 122–129 (2005).
37.
DorflingerLJ. New developments in contraception for US women. Contraception87(3), 343–346 (2013).
38.
Population Council: Population Council announces positive results from a Phase 3 trial of one-year contraceptive vaginal ring. www.popcouncil.org.
HuangYJensenJTBracheVA randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception. Contraception90(6), 565–574 (2014).
World Health Organization: Sexually transmitted infections (STIs) Fact sheet No. 110. http://www.who.int.
43.
ThurmanARClarkMRHurlburtJADoncelGF. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int. J. Womens Health5, 695–708 (2013).
